A novel topical formulation of a BRAF inhibitor significantly reduced acneiform rash associated with anti–epidermal growth factor receptor (EGFR) therapies in patients with colorectal cancer, a ...

The intravenous bispecific antibody amivantamab-vmjw (Rybrevant, Johnson & Johnson) also carries a second-line indication for EGFR exon 20 insertion mutated advanced/metastatic NSCLC, as well as a ...

J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca's Tagrisso By Angus Liu Mar 26, 2025 11:45am Johnson & Johnson AstraZeneca Tagrisso EGFR-mutated lung cancer ...

Key Takeaways Datroway received FDA accelerated approval for EGFR-mutated NSCLC after progression on EGFR-targeted therapy and platinum-based chemotherapy. Clinical trials showed a 45% overall ...

The rate of eGFR decline was –2.78 mL/min/1.73 m² during the first 3 months after SGLT2 inhibitor initiation and stabilized to –0.07 mL/min/1.73 m² per 90 days during months 3 through 12.

For years, Tagrisso has been the standard first-line treatment for EGFR-mutated NSCLC. But that status has recently come under attack from Johnson & Johnson’s combination of Rybrevant and ...

Journal reference: Krauß, D., et al. (2025). EGFR controls transcriptional and metabolic rewiring in KRASG12D colorectal cancer. EMBO Molecular Medicine. doi.org/10.1038/s44321-025-00240-4.

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events (irAEs) that occur when the epidermal growth factor receptor (EGFR ...

In a model, baseline predictors for experiencing a larger acute eGFR dip with empagliflozin included older age, higher baseline eGFR, greater albuminuria, higher systolic blood pressure, lower ...

Patients with EGFR-mutant non-small cell lung cancer (NSCLC) tend to do well on treatments, but eventually their disease may stop responding to therapies, highlighting a need for more treatments that ...